New User? Click here to register

Comment a évoluée l’offre de soin dans le cancer du sein dans les pays émergents ces dernières années ?

Text generated by AI based on an exclusive interview, revised and reviewed by

Dr Jean-Philippe MINART, Cannes, France

February 25, 2023

Yazid BELKACEMI MD, PhD, Radiotherapist, Creteil, France

Yazid BELKACEMI
MD, PhD, Radiotherapist, Creteil, France

Biological and anatomo-pathological characteristics. How to improve financial items.
Frédérique PENAULT-LLORCA
Pathologist, Clermont Ferrand, France
Where does immunotherapy take place in breast cancer, is there a potential in HER2 positive patients?
Hassan GHAZAL
oncologist, Dubai
Where do we stand in developing radionuclides against molecular markers overexpressed on breast cancer (BC) cells such as EGFR-family members?
Willy Vangu
nuclear medicine, Johannesburg, South Africa
Long-term Follow-Up and Survivorship Care
Nivashni MURUGAN
Thoughts on DESTINY-Breast04 for HER2-low metastatic breast cancer.
Joseph GLIGOROV
Oncologist, Paris, France

Leave a Comment cancel

You must be logged in to post a comment.